Pelizzon David R 4
4 · ORTHOPEDIATRICS CORP · Filed Sep 22, 2022
Insider Transaction Report
Form 4
Pelizzon David R
Director
Transactions
- Exercise of In-Money
Common Stock
2022-09-20$0.00/sh+1,525,000$457→ 6,901,764 total(indirect: See footnote) - Exercise of In-Money
Warrants (right to buy)
2022-09-20+1,525,000→ 0 total(indirect: See footnote)Exercise: $0.00→ Common Stock (1,525,000 underlying)
Holdings
- 24,816
Common Stock
Footnotes (2)
- [F1]These securities are held directly by Squadron Capital LLC ("Squadron"). As the President and a member of the Managing Committee of Squadron, the reporting person may be deemed to be the beneficial owner of these securities. The reporting person expressly disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. The inclusion of these securities in this report shall not be deemed to be an admission of beneficial ownership for purposes of Section 16 or for any other purpose.
- [F2]Squadron beneficially owns shares of the Issuer's common stock with a market value in excess of the notification threshold of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"). The warrants could not be exercised until the expiration of all applicable HSR Act waiting periods or the exercise otherwise becomes exempt from the notification requirements thereunder. On September 19, 2022, the waiting period under the HSR Act expired. Once the warrants became exercisable, Squadron Capital LLC was obligated to exercise them within five (5) business days.